Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Crinetics Pharmaceuticals (CRNX) shows strong technical momentum and a high-quality consolidation setup, signaling a potential breakout opportunity for traders.

Crinetics Q3 2025 earnings miss estimates as it transitions to a commercial-stage company following the U.S. launch of its new drug, PALSONIFY.

The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.

On Thursday, the U.S.

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.

Let's have a look at the gap up and gap down stocks in today's session.

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.

Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

The company's drug, Palsonify, treats acromegaly, a condition in which the pituitary gland makes too much growth hormone.

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Crinetics shares PATHFNDR trial data showing oral Palsonify maintained hormone and symptom control in acromegaly patients over 84–96 weeks.

The company presented new data at ENDO 2025 showing that patients who switched from monthly injections to the daily pill maintained hormone control and saw fewer symptom flare-ups over nearly two years.

JP Morgan's survey of endocrinologists finds strong awareness of Crinetics' atumelnant, with positive efficacy impressions. Analysts see long-term potential.

Stifel initiates coverage on CRNX, a clinical-stage pharmaceutical company focused on endocrine diseases and tumors.